| 1 | Changes in employment status and income and workplace organizational support among cancer survivors: A descriptive study in Iran | 1.0 | 1 | Citations (PDF) |
| 2 | Assessing Women’s Preference and Willingness to Pay for Breast Cancer Screening: A Discrete Choice Experiment Approach | 1.0 | 0 | Citations (PDF) |
| 3 | Differentiating benign and hepatocellular carcinoma cirrhotic nodules: radiomics analysis of water restriction patterns with diffusion MRI | 2.0 | 0 | Citations (PDF) |
| 4 | Economic burden of five common cancers in Iran: a systematic review of cost-of-illness with a focus on healthcare resource utilization | 1.7 | 6 | Citations (PDF) |
| 5 | Finding the PSA-based screening stopping age using prostate cancer risk | 1.5 | 2 | Citations (PDF) |
| 6 | Development of a gastric cancer risk calculator for questionnaire-based surveillance of Iranian dyspeptic patients | 1.8 | 3 | Citations (PDF) |
| 7 | Determining the Content of a Melanoma Prevention and Care Mobile Application for Melanoma Patients: A Survey Study | 0.9 | 2 | Citations (PDF) |
| 8 | Challenges and benefits of telepathology in education: lessons learned from COVID-19—a systematic review | 1.1 | 2 | Citations (PDF) |
| 9 | Hospital and post-discharge mortality in COVID-19 patients with a preexisting cancer diagnosis in Iran | 2.3 | 4 | Citations (PDF) |
| 10 | The Cancer Incidence Pattern in Isfahan Province: An Industrial Region in the Central Part of Iran | 1.7 | 6 | Citations (PDF) |
| 11 | Financial cost of end-of-life cancer care in palliative care units (PCUs) and non-PCUs in Iran: insights from low- and middle-income countries | 1.1 | 2 | Citations (PDF) |
| 12 | Regional disparities in cancer survival in Iran: Insight from a National Surveillance of Cancer Survival in Iran (IRANCANSURV) | 1.7 | 6 | Citations (PDF) |
| 13 | Population attributable proportion and number of cancer cases attributed to potentially modifiable risk factors in Iran in 2020 | 2.9 | 14 | Citations (PDF) |
| 14 | Optimal age to stop prostate cancer screening and early detection | 1.0 | 1 | Citations (PDF) |
| 15 | Machine learning-based mortality prediction models for smoker COVID-19 patients | 2.9 | 12 | Citations (PDF) |
| 16 | Using Electronic Health Record System to Establish a National Patient's Registry : Lessons learned from the Cancer Registry in Iran | 2.7 | 8 | Citations (PDF) |
| 17 | Use of sentiment analysis for capturing hospitalized cancer patients' experience from free-text comments in the Persian language | 2.9 | 13 | Citations (PDF) |
| 18 | Economic Burden of Gynecological Cancers in Iran | 1.0 | 20 | Citations (PDF) |
| 19 | Smartphone-based application for self-management of patients with colorectal cancer: development and usability evaluation | 1.9 | 24 | Citations (PDF) |
| 20 | Population-based cancer survival in the Golestan province in the northeastern part of Iran 2007–2012 | 1.7 | 8 | Citations (PDF) |
| 21 | A cost-effectiveness modeling study of treatment interventions for stage I to III esophageal squamous cell carcinoma | 1.5 | 5 | Citations (PDF) |
| 22 | The Lost Productivity Cost of Premature Mortality Owing to Cancers in Iran: Evidence From the GLOBOCAN 2012 to 2018 Estimates | 1.0 | 9 | Citations (PDF) |
| 23 | National surveillance of cancer survival in Iran (IRANCANSURV): Analysis of data of 15 cancer sites from nine population-based cancer registries | 2.9 | 21 | Citations (PDF) |
| 24 | Cost–Benefit Analysis of Human Papillomavirus Vaccine in Iran | 1.1 | 10 | Citations (PDF) |
| 25 | People also looked at | 1.8 | 8 | Citations (PDF) |
| 26 | Cost per DALY averted in low, middle- and high-income countries: evidence from the global burden of disease study to estimate the cost-effectiveness thresholds | 1.5 | 64 | Citations (PDF) |
| 27 | Psychometric properties of the SF-6Dv2 in an Iranian breast cancer population | 1.8 | 13 | Citations (PDF) |
| 28 | Mothers’ preferences and willingness-to-pay for human papillomavirus vaccines in Iran: A discrete choice experiment study | 1.4 | 14 | Citations (PDF) |
| 29 | Requirements of self-management applications for patients with colorectal cancer | 0.0 | 4 | Citations (PDF) |
| 30 | The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017 | 15.8 | 530 | Citations (PDF) |
| 31 | A decision support system for mammography reports interpretation | 2.7 | 13 | Citations (PDF) |
| 32 | Mapping the cancer-specific FACT-B onto the generic SF-6Dv2 | 1.8 | 16 | Citations (PDF) |
| 33 | Comparing the performance of the EQ-5D-5L with two versions of the SF-6Dv2 in patients with breast cancer | 1.0 | 21 | Citations (PDF) |
| 34 | The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 | 15.8 | 336 | Citations (PDF) |
| 35 | Mapping 123 million neonatal, infant and child deaths between 2000 and 2017 | 32.8 | 198 | Citations (PDF) |
| 36 | Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study | 11.6 | 2,104 | Citations (PDF) |
| 37 | Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients | 1.0 | 33 | Citations (PDF) |
| 38 | Mapping EORTC-QLQ-C30 and QLQ-CR29 onto EQ-5D-5L in Colorectal Cancer Patients | 1.2 | 21 | Citations (PDF) |
| 39 | Automated Misspelling Detection and Correction in Persian Clinical Text | 3.3 | 23 | Citations (PDF) |
| 40 | Oncology Information System: A Qualitative Study of Users’ Requirements | 0.9 | 5 | Citations (PDF) |
| 41 | Economic Evaluation of Treatments for Patients with Esophageal Cancer: A Systematic Review | 0.2 | 0 | Citations (PDF) |
| 42 | Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 | 49.6 | 805 | Citations (PDF) |
| 43 | Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 | 49.6 | 6,412 | Citations (PDF) |
| 44 | Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 | 49.6 | 4,121 | Citations (PDF) |
| 45 | Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 | 49.6 | 374 | Citations (PDF) |
| 46 | Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 | 49.6 | 11,286 | Citations (PDF) |
| 47 | Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017 | 49.6 | 399 | Citations (PDF) |
| 48 | Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 | 49.6 | 2,616 | Citations (PDF) |
| 49 | Cancer incidence in the East Azerbaijan province of Iran in 2015–2016: results of a population-based cancer registry | 2.2 | 15 | Citations (PDF) |
| 50 | The economic burden of oral cancer in Iran | 1.6 | 32 | Citations (PDF) |
| 51 | Application of E75 peptide vaccine in breast cancer patients: A systematic review and meta-analysis | 3.4 | 20 | Citations (PDF) |
| 52 | Development of a tool for comprehensive evaluation of population-based cancer registries | 2.7 | 12 | Citations (PDF) |
| 53 | A REVIEW OF ONCOLOGY CLINICAL INFORMATION SYSTEMS- WHAT ARE THE CRITICAL SUCCESS FACTORS AND REASONS FOR SYSTEM FAILURE? | 0.1 | 2 | Citations (PDF) |
| 54 | Economic burden of colorectal cancer in Iran in 2012 | 0.4 | 25 | Citations (PDF) |
| 55 | Serum Antibodies against Helicobacter pylori Neutrophil Activating Protein in Carriers of IL-4 C-590T Genetic Polymorphism Amplify the Risk of Gastritis and Gastric Cancer | 0.7 | 2 | Citations (PDF) |
| 56 | Cost-Effectiveness of Different Cervical Screening Strategies in Islamic Republic of Iran: A Middle-Income Country with a Low Incidence Rate of Cervical Cancer | 1.6 | 18 | Citations (PDF) |
| 57 | Priority Setting for Improvement of Cervical Cancer Prevention in Iran | 0.9 | 32 | Citations (PDF) |
| 58 | Relationship between Spiritual Health and Quality of Life in Patients with Cancer | 0.9 | 15 | Citations (PDF) |
| 59 | Esophageal cancer in Iran; a population-based study regarding adequacy of cancer surgery and overall survival | 1.6 | 11 | Citations (PDF) |
| 60 | Management of Precancerous Cervical Lesions in Iran: A Cost Minimizing Study | 0.9 | 4 | Citations (PDF) |
| 61 | A Systematic Review of Economic Aspects of Cervical Cancer Screening Strategies Worldwide: Discrepancy between Economic Analysis and Policymaking | 0.9 | 27 | Citations (PDF) |
| 62 | Challenges to Promoting Population-Based Cancer Registration in Iran: a Workshop Report | 0.9 | 7 | Citations (PDF) |
| 63 | Epstein-Barr virus associated gastric carcinoma: a report from Iran in the last four decades | 1.9 | 26 | Citations (PDF) |
| 64 | Disability-Adjusted Life Years (DALY) for Cancers in Iran, 1990 to 2016: Review of Findings from the Global Burden of Disease Study. | 0.0 | 4 | Citations (PDF) |
| 65 | IRANCANSURV: A comprehensive analysis of childhood cancer survival in Iran | 2.9 | 0 | Citations (PDF) |
| 66 | A machine learning approach for mortality risk prediction of hospitalized COVID-19 patients with diabetes 0, 2, 100906 | | 1 | Citations (PDF) |
| 67 | Cost-effectiveness of Pembrolizumab in advanced endometrial cancer: A systematic review. | 2.4 | 0 | Citations (PDF) |
| 68 | The Requirements for Smart Cancer Hospitals: An Overview | 0.0 | 0 | Citations (PDF) |
